OGI Stock Analysis: Buy, Sell, or Hold?
OGI - Organigram Global Inc. Common Shares
$0.94
0.00 (-0.43%)
▼
5d:
+0.54%
30d:
-14.07%
90d:
+0.2%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Dec 15, 2026
Get Alerted When OGI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OGI trading at deep discount. Market pricing in -11.7% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: OGI trading at deep discount. Market pricing in -11.7% annual earnings decline, creating value opportunity for patient investors.
In-depth Analysis How we analyze
Valuation Analysis: OGI is currently trading at $0.94, which is considered slightly low relative to its 30-day fair value range of $0.93 to $1.07. From a valuation perspective, the stock is trading at a discount (Forward PE: 39.0) compared to its historical average (56.6). Remarkably, the market is currently pricing in an annual earnings decline of 11.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGI is in a strong uptrend. The price is approaching resistance at $0.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OGI scores 97/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.80 (+839.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OGI is in a strong uptrend. The price is approaching resistance at $0.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OGI scores 97/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.80 (+839.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.93 -
$1.07
Company Quality Score
75/100
(STRONG BUY)
Volume Confirmation
HIGH
Confidence Score
92.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (97/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 839.6% below Wall St target ($8.80)
- BULLISH: Bottoming setup score 97/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$0.93 -
$1.07
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.12
(12.8%)
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$0.96
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
39.02
Wall Street Target
$8.80
(+839.6%)
Revenue Growth (YoY)
49.4%
Profit Margin
28.0%
Valuation Discount vs History
-11.7% cheaper
PE vs Historical
39.0 vs 56.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.7%
(market-implied from PE analysis)
1-Year Target
$0.84
(-10%)
2-Year Target
$0.76
(-19%)
3-Year Target
$0.68
(-27%)
3-Yr Target (if PE normalizes)
(PE: 39→57)
$0.99
(+6%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 39.0, Growth: -94.5%)
$0.68
(+-27%)
Base:
(SPY PE: 19.9, Growth: -94.5%)
$0.35
(-63%)
Bear:
(PE: 16.9, Growth: -94.5%)
$0.30
(-69%)
📈
Valuation based on Current Earnings
Trailing PE: 2.19 | Current EPS (TTM): $0.43
Bull Case
$0.52
(-45%)
Analyst growth -50.0%, PE expands to 2.4
Base Case
$0.47
(-50%)
Market implied -50.0%, PE stable at 2.2
Bear Case
$0.64
(-32%)
Severe decline -20.0%, PE contracts to 1.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 39.0 to 56.6
Stabilization Target:
$1.36
(+45.0%)
PE Expansion Potential:
+45.0%
Share & Embed Analysis
Last updated: October 23, 2026 7:31 AM ET
Data refreshes hourly during market hours. Next update: 8:31 AM
Data refreshes hourly during market hours. Next update: 8:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
